Revenue segments as reported by the company.

Collaboration revenue

Grant revenue

Product sales

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and Development

General and Administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Moderna

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Moderna reports robust earnings, eyes growth through innovative vaccines

Moderna's strong financial performance and strategic investments in R&D and commercial activities position it well for future growth. While facing challenges in product sales and regulatory uncertainties, the company's focus on innovation and expanding its product portfolio presents opportunities for continued success in the healthcare sector.

Moderna posts strong Q1 earnings, eyes market expansion opportunities

Moderna's Q1 performance reflects strong earnings, robust R&D investments, and strategic commercial negotiations.
The company's strengths lie in market positioning, cost optimization, asset prioritization, and collaboration opportunities.
Challenges include contract timing uncertainties, market competition, and regulatory approval processes.
Amidst challenges, Moderna sees opportunities in revenue growth, market expansion, program advancements, and partnership developments.

Moderna reports Q2 performance, innovation strength, margin challenges

Moderna's Q2 performance reflects significant investments and revised COVID-19 sales expectations.
The company's strengths lie in innovation, oncology progress, and preparations for upcoming product launches.
Challenges include margin guidance revisions and differing views on vaccine development strategies.
Opportunities exist in vaccine combinations, market positioning, and accelerated enrollment in flu studies.

Moderna reports $1.8B Spikevax sales, eyes profitability in 2024

Moderna's Q3 2023 Earnings Call highlighted strong Spikevax sales, plans for new vaccine launches, and a focus on profitability. Despite challenges like restructuring charges, the company sees opportunities in expanding its product portfolio and market share.

Moderna reports $6.1B in 2023 sales, anticipates $4B in 2024

Moderna's financials reflect market transition impact with a focus on cost management.
Strong pipeline progress and confidence in vaccine efficacy milestones for 2024.
Challenges include net loss, anticipated sales decrease, and ongoing regulatory discussions.
Opportunities lie in potential vaccine approvals, partnerships, and therapeutic advancements.

Moderna reports Q1 sales dip, eyes growth in pipeline

Moderna's Q1 2024 performance reflects a shift in sales dynamics with a focus on pipeline progress and financial discipline.
While facing challenges in market dynamics and transparency, Moderna's strategic focus on COVID-19 and pipeline advancements positions it for growth.
Opportunities lie in expanding vaccine delivery methods, international market penetration, and therapeutic advancements in various programs.

Moderna reports robust Q2 earnings, focuses on innovation and cost management

Moderna's Q2 2024 earnings call highlighted strong financial performance, strategic achievements in vaccine development, and operational improvements. While facing challenges in sales and competitive pressures, the company remains focused on innovation and cost management. Opportunities lie in upcoming milestones and the potential of its diverse clinical programs.

Moderna reports robust Q3 earnings, eyes global expansion and innovation

Moderna's Q3 2024 earnings call showcased strong financial performance, cost-saving initiatives, and a robust pipeline of products in development.
While facing legal challenges and market competition, the company's strategic strengths lie in market share, global expansion plans, and financial stability.
Opportunities in education, international markets, and product development position Moderna for continued growth and innovation in the healthcare sector.
Navigating challenges and leveraging opportunities will be key for Moderna to maintain its leadership in the COVID vaccine market and drive future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

They'll determine the pace of growth ahead.

3 Crucial Things I'll Be Looking for in Moderna's Earnings Report

CAMBRIDGE, Mass. & EMERYVILLE, Calif.--(BUSINESS WIRE)--Moderna and Metagenomi Establish Collaboration to Develop Next-Generation In Vivo Gene Editing Therapeutics

Moderna and Metagenomi Establish Collaboration to Develop Next-Generation In Vivo Gene Editing Therapeutics

ABVC BioPharma

ANI Pharma

Sanofi

Sorrento Therapeutics Inc

Biotech stocks to note as the coronavirus pandemic rages on across the globe.

Best Biotech Stocks To Buy Now? 5 To Check Out In November 2021

Investor focus is likely to be on the sales outlook for Moderna's (MRNA) authorized coronavirus vaccine on the third-quarter earnings call.

Moderna (MRNA) to Report Q3 Earnings: What's in the Cards?

Shares in Moderna Inc. dropped at least 5% as trading opened Monday after a delay in the decision to approve the COVID-19 vaccine for adolescents ages 12-17.

Moderna shares tank after FDA delays COVID vaccine for 12- to 17-year-olds

Moderna Inc (NASDAQ: MRNA) is trading lower Monday morning after the U.S. Food and Drug Administration delayed approval of the company's Emergency Use Authorization request for the use of its COVID-19 vaccine in adolescents 12 to 17 years of age. The FDA informed Moderna that it will require additional time to evaluate the risk of myocarditis after vaccination.

Why Moderna Shares Are Trading Lower Today

Moderna Inc (NASDAQ: MRNA) said that the FDA would require additional time to complete its assessment of its COVID-19 vaccine for use in adolescents aged 12 to 17 years. The FDA may not complete the Moderna's shot review before January 2022, dealing with a potential setback to the timing of an emergency use authorization (EUA) for that age group.

FDA Delays Approval For Moderna's COVID-19 Shot In Teenagers: What You Need To Know

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna Announces Pledge to Achieve Net-Zero Carbon Emissions Globally by 2030

Moderna Announces Pledge to Achieve Net-Zero Carbon Emissions Globally by 2030

Moderna Inc. MRNA, -0.78% said it would delay filing a request with the U.S. Food and Drug Administration to emergency use authorization of its COVID-19 vaccine at the 50 µg dose level in children ages 6 to 11, to give the regulator time to complete its review of an earlier submission for use in adolescents 12 to 17 years of age. The company announced the news in a Sunday release, in which it said the FDA had informed it that it needed more time to complete its assessment of the request for the 100 µg dose level in 12-to-17-year-olds.

Moderna says FDA needs more time to review COVID vaccine in 12-to-17-year olds

"The Company is fully committed to working closely with the FDA to support their review and is grateful to the FDA for their diligence," Moderna said.

The FDA is delaying the review of Moderna's COVID-19 vaccine for kids

Moderna said the FDA needs more time to complete its review of its Covid-19 vaccine for 12-to-17-year-olds before granting emergency use authorization.

Moderna says FDA needs more time to review its Covid vaccine for teens

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna Provides Update on Timing of U.S. Emergency Use Authorization of its COVID-19 Vaccine for Adolescents

Moderna Provides Update on Timing of U.S. Emergency Use Authorization of its COVID-19 Vaccine for Adolescents

Moderna Inc (NASDAQ: MRNA) has announced an agreement with Gavi, the Vaccine Alliance, to supply up to 116.5 million doses of its COVID-19 vaccine to be delivered in Q2 of 2022.  The exercise of these options for additional doses represents an increase from an earlier agreement for 60 million doses.

Moderna To Supply Additional COVID-19 Vaccine Doses To COVAX Alliance

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna Announces Additional Supply for Q2 2022 of Vaccine for COVAX To Help End COVID-19 Pandemic in Lowest Income Countries

Moderna Announces Additional Supply for Q2 2022 of Vaccine for COVAX To Help End COVID-19 Pandemic in Lowest Income Countries

Moderna (MRNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Moderna (MRNA) Reports Next Week: Wall Street Expects Earnings Growth

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna Named a Top Employer by Science for Seventh Consecutive Year

Moderna Named a Top Employer by Science for Seventh Consecutive Year

In the latest trading session, Moderna (MRNA) closed at $340.88, marking a -1.41% move from the previous day.

Moderna (MRNA) Dips More Than Broader Markets: What You Should Know

Moderna's CEO is confident the company's vaccine will be approved for adolescents.

Teens Could Get Moderna Covid-19 Vaccine In Coming Weeks, Children 6-11 By End Of Year, CEO Says

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna Announces First Participant Dosed in Phase 3 Pivotal Registration Study of its mRNA Cytomegalovirus (CMV) Vaccine

Moderna Announces First Participant Dosed in Phase 3 Pivotal Registration Study of Its mRNA Cytomegalovirus (CMV) Vaccine

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna Announces Swissmedic Authorizes Booster Dose of Moderna's COVID-19 Vaccine

Moderna Announces Swissmedic Authorizes Booster Dose of Moderna's COVID-19 Vaccine

Shares of Moderna Inc. MRNA, +7.05% gained 2.2% in premarket trading on Tuesday after the company said it signed a deal to supply the African Union with up to 110 million doses of its COVID-19 vaccine. The first 15 million doses are set to be delivered before the end of this year; the next 35 million in the first quarter of 2022, and up to 60 million in the second quarter of next year.

Moderna to supply African Union with up to 110 million doses over the next year

Hot demand for vaccine doses might start cooling soon.

Here's What to Look for in Moderna's Upcoming Earnings Report

Moderna's announcement comes at a time when wealthy nations and vaccine makers face intense criticism for failing to deliver adequate vaccine doses to poorer nations.

Moderna Agrees To Sell 110 Million Covid Vaccine Doses To African Nations Amid Questions About Vaccine Equity

Shares of Moderna (NYSE: MRNA) traded 7% higher on Monday, after receiving positive results from their Covid 19 vaccine for kids. Moderna is also announcing their results in the first week of November and investors are expecting strong results, so is this a time to buy Moderna now?

With results coming out soon, is Moderna a good buy now?

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna Announces Memorandum of Understanding to Supply up to 110 Million Doses of Its COVID-19 Vaccine to the African Union

News for Moderna Stock (MRNA)